Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BGB-B2033 · 3 trials · 8 indications
OS is defined as the time from randomization to the date of death from any cause.
ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) with confirmation per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on Independent Review Committee (IRC) assessments.
Number of participants with AEs and SAEs characterized by type, frequency, severity (as graded by the National Cancer Institute- Common Terminology Criteria for Adverse Events Version 5.0 \[NCI-CTCAE v 5.0/American Society for Transplantation and Cellular Therapy \[ASTCT\] for cytokine release syndrome \[CRS\] and immune effector cell-associated neurotoxicity syndrome \[ICANS\]), timing, seriousness, and relationship to study therapy; assessment of adverse events meeting protocol-defined dose-limiting toxicity (DLT) criteria
The MTD or MAD is defined as the highest dose that is tolerable or the highest dose administered, respectively.
The RP2D(s) will be determined based on a biologically effective dose by taking the totality of available preclinical and clinical data, including safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity, into consideration
ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) using Response Evaluations Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
| Arm | Type | Description |
|---|---|---|
| BGB-B2033 | EXPERIMENTAL | Participants are randomized to receive BGB-B2033 until disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study, whichever occurs first. |
| Investigator's choice: Lenvatinib OR sorafenib | ACTIVE_COMPARATOR | Participants are randomized to receive either lenvatinib or sorafenib, selected by the investigator before treatment, until disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study, whichever occurs first. |
| BGB-B2033 Monotherapy | EXPERIMENTAL | Participants will receive BGB-B2033 intravenously until progressive disease, unacceptable toxicity, or withdrawal of consent. |
| Part A (Monotherapy Dose Escalation and Safety Expansion) | EXPERIMENTAL | Participants will receive ascending dose levels of BGB-B2033 monotherapy |
| Part B (Doublet Run-in) | EXPERIMENTAL | Participants will receive BGB-B2033 in combination with tislelizumab and to inform the starting dose of BGB-B2033 for subsequent triplet dose escalation. |
| Part B (Triplet Dose Escalation) | EXPERIMENTAL | Participants will receive BGB-B2033 in combination with tislelizumab and bevacizumab to determine the maximum tolerated dose (MTD), maximum administered dose (MAD), and recommended dose for expansion (RDFE) of the combination. |
| Part B (Triplet and Doublet Safety Expansion) | EXPERIMENTAL | Safety expansion arm for each combination therapy cohort (triplet and doublet) |
| Part C (Asia Monotherapy Dose Expansion in HCC) | EXPERIMENTAL | Participants in Asian countries with HCC will receive BGB-B2033 as monotherapy. |
| Part D (US Monotherapy Dose Expansion in HCC) | EXPERIMENTAL | Participants in the United States (US) with HCC will receive BGB-B2033 as monotherapy. |
| Part E (Monotherapy Dose Expansion in HCC) | EXPERIMENTAL | Participants with HCC will receive BGB-B2033 as monotherapy. |
| Name | Type | Description |
|---|---|---|
| BGB-B2033 | DRUG | Administered intravenously |
| Lenvatinib | DRUG | Administered by mouth as an oral capsule once daily |
| Sorafenib | DRUG | Administered by mouth as an oral tablet twice daily |
| Tislelizumab | DRUG | Administered by intravenous infusion |
| Bevacizumab | DRUG | Administered by intravenous infusion |
Key Inclusion Criteria: 1. Participants must have histologically confirmed Hepatocellular Carcinoma (HCC) that is not amenable to curative surgical or locoregional therapies. 2. Participants must have documented disease progression or intolerance after at least 1 but not exceeding 2 prior lines of ...
BGB-B2033 is being developed for hepatocellular carcinoma, including advanced and metastatic liver cancer. It is also being studied in other GPC3-positive tumors such as squamous non-small cell lung cancer, alpha-fetoprotein-producing gastric cancer, and extragonadal yolk sac tumors. It is an investigational biologic and has not been approved for any use.
BGB-B2033 targets GPC3, or glypican-3, a cell surface protein. GPC3 is the molecular target of this biologic agent, and the clinical program includes a trial enrolling participants with GPC3-positive squamous non-small cell lung cancer alongside hepatocellular carcinoma cohorts.
BGB-B2033 is being developed by BeOne Medicines Ltd., which trades under the ticker ONC. The company is running the clinical program for the drug in hepatocellular carcinoma and other advanced solid tumors, including a Phase 1/2 study combining it with tislelizumab with or without bevacizumab.
BGB-B2033 is in Phase 2 development for hepatocellular carcinoma, and a Phase 3 study has also been registered. The drug is investigational and is not FDA approved. It has received Fast Track and Orphan Drug designations from the FDA for its liver cancer program.
BGB-B2033 is studied in NCT06427941, a recruiting Phase 1/2 trial in advanced or metastatic solid tumors, alone or with tislelizumab with or without bevacizumab. NCT07911683 is a Phase 2 study in advanced hepatocellular carcinoma, and NCT07836530 is a Phase 3 study comparing BGB-B2033 with sorafenib or lenvatinib in relapsed hepatocellular carcinoma.
The Phase 1/2 study of BGB-B2033, NCT06427941, is an uncontrolled, non-randomized, open-label design enrolling up to 630 participants across sites in the United States, Brazil, China, France, Italy, Japan, New Zealand, Puerto Rico, and South Korea. The registered Phase 3 study NCT07836530 plans 492 participants and compares BGB-B2033 with sorafenib or lenvatinib.